(IRON) Disc Medicine - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2546041011
IRON EPS (Earnings per Share)
IRON Revenue
IRON: Bitopertin, DISC-0974, DISC-3405, DISC-0998
Disc Medicine Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for serious hematologic diseases. With a robust pipeline of clinical and preclinical product candidates, the company aims to modify fundamental biological pathways associated with red blood cell formation and function. Its lead candidates target heme biosynthesis and iron homeostasis, addressing conditions such as erythropoietic porphyrias, anemia of myelofibrosis, and polycythemia vera.
The companys pipeline includes several promising assets, including bitopertin, DISC-0974, and DISC-3405, which are being developed for various hematologic disorders. Additionally, preclinical programs such as DISC-0998 show potential for treating anemia associated with inflammatory diseases. With a strong research foundation, Disc Medicine is well-positioned to address significant unmet medical needs in the hematology space.
From a technical analysis perspective, IRONs stock price has been trending upwards, with a current price of 53.71 and a 20-day SMA of 48.95, indicating a bullish sentiment. The stock is also above its 200-day SMA of 52.98, suggesting a long-term uptrend. With an ATR of 2.64, representing a 4.91% daily volatility, investors can expect significant price movements. Given the current technical indicators and fundamental data, including a market cap of 1641.67M USD and a negative RoE of -22.61, a forecast for IRONs stock price could be around 70-80 USD in the next 6-12 months, driven by potential pipeline advancements and increased investor confidence.
To achieve this forecast, Disc Medicine will need to continue to demonstrate progress in its clinical trials, particularly with its lead candidates. Positive trial results, regulatory approvals, and eventual commercialization of its products could drive the stock price upwards. Conversely, any setbacks or negative trial results could lead to a decline in the stock price. As a Trading Analyst, it is essential to closely monitor the companys developments and adjust the forecast accordingly.
Additional Sources for IRON Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
IRON Stock Overview
Market Cap in USD | 1,642m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2020-08-12 |
IRON Stock Ratings
Growth Rating | -55.1 |
Fundamental | -48.7 |
Dividend Rating | 0.0 |
Rel. Strength | 22.9 |
Analysts | 4.64 of 5 |
Fair Price Momentum | 36.39 USD |
Fair Price DCF | - |
IRON Dividends
Currently no dividends paidIRON Growth Ratios
Growth Correlation 3m | 14.8% |
Growth Correlation 12m | 18.1% |
Growth Correlation 5y | -54.4% |
CAGR 5y | -31.28% |
CAGR/Max DD 5y | -0.32 |
Sharpe Ratio 12m | -0.30 |
Alpha | -4.45 |
Beta | 1.844 |
Volatility | 65.96% |
Current Volume | 407.7k |
Average Volume 20d | 377.9k |
As of June 18, 2025, the stock is trading at USD 50.05 with a total of 407,716 shares traded.
Over the past week, the price has changed by -5.69%, over one month by +0.73%, over three months by -2.38% and over the past year by +11.57%.
Probably not. Based on ValueRay´s Fundamental Analyses, Disc Medicine (NASDAQ:IRON) is currently (June 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -48.68 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRON is around 36.39 USD . This means that IRON is currently overvalued and has a potential downside of -27.29%.
Disc Medicine has received a consensus analysts rating of 4.64. Therefor, it is recommend to buy IRON.
- Strong Buy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, IRON Disc Medicine will be worth about 43.7 in June 2026. The stock is currently trading at 50.05. This means that the stock has a potential downside of -12.75%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 99.2 | 98.2% |
Analysts Target Price | 99.2 | 98.2% |
ValueRay Target Price | 43.7 | -12.7% |